Stock Analysis

Undervalued Small Caps With Insider Action In February 2025

NZSE:ARG
Source: Shutterstock

In February 2025, global markets are navigating a complex landscape marked by geopolitical tensions and consumer spending concerns, with major indices like the S&P 500 experiencing sharp fluctuations. Amidst this backdrop, small-cap stocks have faced their own set of challenges, as reflected in the Russell 2000's recent decline. In such an environment, identifying promising small-cap opportunities often involves looking at companies that demonstrate resilience through strong fundamentals and strategic insider actions that signal confidence in their future prospects.

Top 10 Undervalued Small Caps With Insider Buying

NamePEPSDiscount to Fair ValueValue Rating
Bytes Technology Group20.6x5.2x19.18%★★★★★☆
Maharashtra Seamless11.2x1.8x42.85%★★★★★☆
Speedy HireNA0.2x26.26%★★★★★☆
Gamma Communications22.8x2.3x34.50%★★★★☆☆
ABG Sundal Collier Holding11.7x1.9x22.86%★★★★☆☆
Franchise Brands39.5x2.0x24.46%★★★★☆☆
CVS Group28.5x1.2x38.97%★★★★☆☆
Mark Dynamics Indonesia12.7x4.1x3.66%★★★☆☆☆
Fourlis Holdings8.2x0.4x-220.32%★★★☆☆☆
Avia Avian13.8x3.2x19.84%★★★☆☆☆

Click here to see the full list of 181 stocks from our Undervalued Small Caps With Insider Buying screener.

Let's uncover some gems from our specialized screener.

Eurocommercial Properties (ENXTAM:ECMPA)

Simply Wall St Value Rating: ★★★★★☆

Overview: Eurocommercial Properties is a real estate investment company specializing in retail property management and leasing, with a market capitalization of approximately €1.56 billion.

Operations: The primary revenue stream is derived from real estate rentals, with recent quarterly revenue reaching €266.26 million. The cost of goods sold (COGS) for the same period was €76.70 million, resulting in a gross profit margin of 71.19%. Operating expenses include general and administrative costs and sales & marketing expenses, which were €11.50 million and €3.38 million respectively in the latest quarter. Net income margin has shown variability, recently recorded at 0.08% for the quarter ending September 2024.

PE: 5867.7x

Eurocommercial Properties, a smaller player in the real estate sector, has experienced insider confidence with share purchases over the past six months. Despite current profit margins of 0.08%, significantly down from last year's 14.6%, earnings are projected to grow by 41% annually. However, interest payments remain inadequately covered by earnings. One-off items have impacted financial results, hinting at potential for improved quality in future earnings as these factors normalize.

ENXTAM:ECMPA Share price vs Value as at Feb 2025
ENXTAM:ECMPA Share price vs Value as at Feb 2025

Argosy Property (NZSE:ARG)

Simply Wall St Value Rating: ★★★★★☆

Overview: Argosy Property is a New Zealand-based real estate investment trust focusing on commercial property investments across retail, office, and industrial sectors with a market capitalization of NZ$1.23 billion.

Operations: Argosy Property's revenue primarily comes from its operations, with a gross profit margin showing a gradual decline from 78.32% to 75.08% over the observed periods. The company experiences significant non-operating expenses, which have impacted its net income negatively in recent periods, leading to negative net income margins as low as -0.73%. Operating expenses remain relatively stable but are overshadowed by the increasing non-operating costs contributing to financial challenges.

PE: -283.6x

Argosy Property, a smaller company in the property sector, is attracting attention with its recent strategic leasing activities. They secured a 12-year lease with Bascik Transport and a 10-year agreement with Viatris Ltd., both targeting eco-friendly standards. However, all liabilities stem from external borrowing, posing potential risks. Despite this, earnings are expected to grow by 29% annually. Insider confidence is reflected through share purchases over the past year, indicating belief in future growth prospects despite financial challenges.

NZSE:ARG Share price vs Value as at Feb 2025
NZSE:ARG Share price vs Value as at Feb 2025

Biotage (OM:BIOT)

Simply Wall St Value Rating: ★★★★★☆

Overview: Biotage is a company that specializes in healthcare software solutions, with a market capitalization of approximately SEK 22.35 billion.

Operations: The company's revenue is primarily derived from healthcare software, amounting to SEK 2.06 billion. Over the observed periods, the gross profit margin has shown a trend of increase, reaching 62.69% by December 2024. Cost of goods sold (COGS) and operating expenses are significant components of its cost structure, with sales and marketing being the largest expense within operating costs.

PE: 33.9x

Biotage, a smaller company in its sector, recently announced earnings with full-year sales reaching SEK 2.06 billion, up from SEK 1.86 billion the previous year. Net income also saw an increase to SEK 284 million from SEK 246 million. Despite a volatile share price over the past three months and reliance on higher-risk funding sources, insider confidence is evident through recent share purchases by key personnel. The company plans to propose a dividend increase to SEK 1.65 per share for shareholders at the upcoming AGM, reflecting steady financial health and growth potential despite challenges in funding stability.

OM:BIOT Share price vs Value as at Feb 2025
OM:BIOT Share price vs Value as at Feb 2025

Make It Happen

  • Take a closer look at our Undervalued Small Caps With Insider Buying list of 181 companies by clicking here.
  • Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
  • Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Ready For A Different Approach?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com